Table 9.

Molecular profiling studies on SSTR signaling in pNETs.

Technique	Reference	Key Findings
RT PCR and IHC	[230]	mRNA amplification of SSTR1 in 90.1%, SSTR2 in 84.8%, SSTR3 in 78.8%, SSTR4 in 24.2% and SSTR5 in 42.4% of pNET cases. Positive SSTR2 immunoreactivity in 15 of 22 tumors (68.2%), SSTR3 in 8 of 22 (36.4%), and SSTR5 in 14 of 22 (63.6%).
Microarray and IHC	[88]	SSTR2 expression is significantly upregulated in NF-pNETs compared to insulinomas.
IHC	[239]	Mild to strong immunoreactivity for SSTR2A observed in 15 out of 16 (94%) pNETs.
	[238]	Positive (IHC score 1 to 4) SSTR2A immunostaining in 63% of 79 pNETs. Negative staining correlated with poor outcomes.
	[185]	Positive SSTR2A and SSTR5 staining in 68% and 58% of 44 pNETs, respectively.
	[240]	Immunoreactivity for SSTR1 in 40%, SSTR2A in 90%, SSTR2B in 39%, SSTR3 in 51% and SSTR5 in 76% of 71 NETS of the GI tract and lungs.
	[241]	Positive immunostaining of SSTR1 and SSTR2 in 100% of 11 G1 and G2 NETs of the GI tract and lungs.
	[229]	Positive SSTR2A and SSTR5 staining in 86% and 35%, respectively, of 99 pNETs. Positive SSTR2A expression correlated with better overall survival.